C-188-9
As of the edition of 20 October 2026, C-188-9 is a small molecule: in active development; acts on STAT3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 7, 3 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Skin and connective tissue; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| STAT3 | Signal transducer and activator of transcription 3 | P40763 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 1 | 1 | 2 |
| Phase 2 | 3 | 1 | 1 | 1 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Tvardi Therapeutics | Lead sponsor of trials | 2017 to now |